Analysis of prognostic factors in childhood advanced stage Hodgkin lymphoma: A retrospective study.

Dongre, Amol; Arora, Brijesh; Banavali, Shripad; Gulia, Seema; Laskar, Siddhartha; Shet, Tanuja; Kembhavi, Seema

doi:10.1200/jco.2014.32.15_suppl.e21000

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B-symptoms were present in 25 (42.4%) patients. Although presence of Bsymptoms have been found to be bad prognostic factor [26] [27], some studies have not shown such significant prognostic effect [28]. Our results did not show significant worse outcome for children with B-symptoms, which may be related to the risk stratified treatment approach that may have diminished the influence of this prognostic factor.…”

Section: Discussioncontrasting

confidence: 47%

Impact of using combined chemotherapy regimen in children with Hodgkin lymphoma in countries with limited resources: a single center experience in Iraq

2023

JPTCP

View full text Add to dashboard Cite

Objective/Background: Data about Hodgkin lymphoma (HL) in developing countries are scattered. The aim of this study is to present clinical features and outcome of children with HL using combined different chemotherapy regimens. Response-based approach was applied irrespective of risk stratification. Methods: Patients aged 18 years and younger who were diagnosed with HL between January 2014 and December 2021 in a cancer center in Iraq, were recruited. Patients were stratified into three risk groups. Initial treatment with induction chemotherapy (i.e., 2 cycles of ABVD) was applied to all patients. Patients who achieved complete radiological response to induction chemotherapy continued with 4-6 cycles of ABVD; radiotherapy was omitted. Patients with slow early response received 3 cycles of COPDac after 3rd cycle of ABVD, followed by radiotherapy. Results: fifty-nine patients were enrolled in this study. The median age was 7 years. Twenty (33.9%) patients were stage III, followed by stage II (32.2%). Twenty-five patients had B symptoms. Initial splenic involvement was found in 11 patients. Approximately one third of patients had bulky disease (n = 19; 32.2%). The most common histology was mixed cellularity (n = 44). The median follow-up was 2.7 year (range from 0.1 to 7.5 years). The 5-year estimates of survival and EFS were 92% and 78% ±10%, respectively. Only bulky disease had a significant negative influence on the outcome. Conclusion: Good outcomes for pediatric HL patients can be achieved in low and middle income countries. Response-based therapy approach is feasible to reduce long term treatment-related sequel.

show abstract

Section: Discussioncontrasting

confidence: 47%

Impact of using combined chemotherapy regimen in children with Hodgkin lymphoma in countries with limited resources: a single center experience in Iraq

2023

JPTCP

View full text Add to dashboard Cite

show abstract

Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk‐adapted approach in a tertiary cancer center in India

Parambil

Narula

Prasad

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundClassical Hodgkin lymphoma (cHL) has excellent survival rates, but late effects are an issue and dictate modern approaches. We analyzed the clinical profile and outcome of cHL treated on a risk‐adapted approach aimed at reducing late effects while improving historical outcomes at our center.ProcedureChildren (≤15 years) consecutively treated for cHL from January 2013 through December 2016 were retrospectively analyzed. 18FDG‐PET‐CT–based staging and response assessment was done after two cycles for early response (ERA) and end of chemotherapy (late‐response assessment [LRA]) if not in complete response (CR; Deauville < 4) at ERA. Stages IA/IB/IIA were low risk (LR) and received two cycles of ABVD (adriamycin/bleomycin/vinblastine/dacarbazine). Stages IAX/IBX/IIAX/IIB/IIIA were intermediate risk (IR), and stages IIBE/IIBX/IIIAE/IIIAX/IIIB/IVA/IVB were high risk (HR). Both received two cycles of OEPA (oncocristine/etoposide/prednisolone/adriamycin). Those in ERA‐CR received two cycles of ABVD if LR, and two and four cycles of COPDac (cyclophosphamide/oncocristine/prednisolone/dacarbazine), respectively, for IR and HR. Involved‐field radiotherapy (IFRT) was given to bulky sites and ERA < CR. Those at LRA < CR (Deauville < 3) or progression at any stage received salvage regimens.ResultsIn the study period, 126 patients were identified who received the above protocol. There were 12 LR, and 114 advanced staged Hodgkin lymphoma (AHL) (18, IR; 96, HR) of which 91 (79.8%) had bulky sites. Eight (66.6%) LR and 93 (83%) AHL patients achieved ERA‐CRs. IFRT was given to 4 (33.3%) LR patients with ERA < CR, and 92 (80.7%) of AHL (91 bulky sites; 1 ERA < CR). At a median follow‐up of 31 months (range, 17–62), three‐year event‐free survival (EFS) and overall survival (OS) were both 100% for LR, and 94.4% (95% CI, 66.0%–99.2%) for IR, whereas for HR it was 90.3% (95% CI, 82.2%–94.8%) and 92.6% (95% CI, 85.2%–96.4%), respectively.ConclusionsChildren with HL have favorable outcomes with manageable toxicities when treated on a risk‐stratified and adapted approach. A high proportion of AHL have bulky disease necessitating IFRT, a concern that will have to be factored in future strategies.

show abstract

Analysis of prognostic factors in childhood advanced stage Hodgkin lymphoma: A retrospective study.

Cited by 2 publications

References 0 publications

Impact of using combined chemotherapy regimen in children with Hodgkin lymphoma in countries with limited resources: a single center experience in Iraq

Impact of using combined chemotherapy regimen in children with Hodgkin lymphoma in countries with limited resources: a single center experience in Iraq

Clinical profile and outcome of classical Hodgkin lymphoma treated with a risk‐adapted approach in a tertiary cancer center in India

Contact Info

Product

Resources

About